Literature DB >> 1086856

Pulmonary abnormalities in intermediate alpha-1-antitrypsin deficiency.

W J Hall, R W Hyde, R H Schwartz, G S Mudholkar, D R Webb, Y P Chaubey, P L Townes.   

Abstract

Pulmonary function studies were carried out in a group of asymptomatic nonsmoking adults with intermediate alpha-1-antitrypsin deficiency who were attending an early disease detection unit in Rochester, N. Y. All subjects were identified by specific protease inhibitor (Pi) typing. Fifteen MZ and 14 MS subjects who had never smoked cigarettes were matched by sex and age to MM controls. Spirometry, static lung volumes, and single breath-diffusing capacity were identical in all Pi type groups with no statistically significant differences noted. Maximal expiratory flow volume curves were obtained in all subjects. MZ subjects demonstrated statistically impaired maximal flow rates at 75%, 50%, and 25% of vital capacity compared to their MM controls. Total pulmonary resistance by the oscillometric method was measured at 3, 5, 7, and 9 cycle/s in the same subjects. Increased frequency dependence of resistance (defined as the difference between total pulmonary resistance at 3 cycle/s and 9 cycle/s) was observed in MZ subjects compared to MM controls. No differences were noted by this method in MS-MM pairs. The data suggest that detectable mechanical abnormalities are present in subjects with the MZ phenotype, even in the absence of established risk factors such as cigarette smoking and high air pollution.

Entities:  

Mesh:

Year:  1976        PMID: 1086856      PMCID: PMC333273          DOI: 10.1172/JCI108558

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  The Veterans Administration-Army cooperative study of pulmonary function. I. Clinical spirometry in normal men.

Authors:  R C KORY; R CALLAHAN; H G BOREN; J C SYNER
Journal:  Am J Med       Date:  1961-02       Impact factor: 4.965

2.  A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide.

Authors:  W S BLAKEMORE; R E FORSTER; J W MORTON; C M OGILVIE
Journal:  J Clin Invest       Date:  1957-01       Impact factor: 14.808

3.  A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects.

Authors:  A B DUBOIS; S Y BOTELHO; G N BEDELL; R MARSHALL; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

4.  Mechanical factors in distribution of pulmonary ventilation.

Authors:  A B OTIS; C B MCKERROW; R A BARTLETT; J MEAD; M B MCILROY; N J SELVER-STONE; E P RADFORD
Journal:  J Appl Physiol       Date:  1956-01       Impact factor: 3.531

5.  Neutral leucocyte proteases and elastase inhibited by plasma alpha 1 -antitrypsin.

Authors:  K Ohlsson
Journal:  Scand J Clin Lab Invest       Date:  1971-11       Impact factor: 1.713

6.  The maximum expiratory flow-volume in the evaluation of patients with lung disease. A comparative study with standard pulmonary function tests.

Authors:  G P Lord; K Gazioglu; N Kaltreider
Journal:  Am J Med       Date:  1969-01       Impact factor: 4.965

7.  Spirometric standards for healthy nonsmoking adults.

Authors:  J F Morris; A Koski; L C Johnson
Journal:  Am Rev Respir Dis       Date:  1971-01

8.  Contribution of compliance of airways to frequency-dependent behavior of lungs.

Authors:  J Mead
Journal:  J Appl Physiol       Date:  1969-05       Impact factor: 3.531

9.  Antitrypsin deficiency in pulmonary disease: the significance of intermediate levels.

Authors:  M H Welch; M E Reinecke; J F Hammarsten; C A Guenter
Journal:  Ann Intern Med       Date:  1969-09       Impact factor: 25.391

10.  A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease.

Authors:  A B DUBOIS; S Y BOTELHO; J H COMROE
Journal:  J Clin Invest       Date:  1956-03       Impact factor: 14.808

View more
  5 in total

1.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

2.  Lung distensibility and airway function in intermediate alpha 1-antitrypsin deficiency (Pi MZ).

Authors:  S F Tattersall; R P Pereira; D Hunter; G Blundell; N B Pride
Journal:  Thorax       Date:  1979-10       Impact factor: 9.139

Review 3.  Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

Authors:  C P Hersh; M Dahl; N P Ly; C S Berkey; B G Nordestgaard; E K Silverman
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

4.  Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease.

Authors:  J E Gadek; J D Fulmer; J A Gelfand; M M Frank; T L Petty; R G Crystal
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

5.  Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.

Authors:  J E Gadek; H G Klein; P V Holland; R G Crystal
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.